1-(Tert-butoxycarbonyl)-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(Tert-butoxycarbonyl)-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid
• 英文别名: 4-ethoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-3-carboxylic acid
• 化学式: C₁₃H₂₁NO₆
• 分子量: 287.31
• InChiKey: BHOJIKSQYLVZHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  93.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE PYRROLIDINE-3,4-DICARBOXAMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005092881A1

  公开（公告）日：2005-10-06

  The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of Formula (I) ; wherein Rl to R9 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

  这项发明涉及一种新型的 Formula (I) 中的吡咯烷-3,4-二羧酰胺衍生物；其中 R1 到 R9 和 X 如描述和索赔中定义的那样，以及其生理上可接受的盐。这些化合物抑制凝血因子 Xa，可用作药物。
• PENTACYCLIC HETEROCYCLES
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20200283452A1

  公开（公告）日：2020-09-10

  The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

  本发明提供了由式(I)至(XVII)表示的化合物或其药学上可接受的盐：
• Organic Compounds
  申请人：Ehrhardt Claus

  公开号：US20080194549A1

  公开（公告）日：2008-08-14

  The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.

  本发明涉及使用(3,4-二-, 3,3,4-三-, 3,4,4-三-或3,3,4,4-四-)取代吡咯烷化合物制备治疗依赖于肾素活性的疾病的药物制剂；使用该类化合物治疗依赖于肾素活性的疾病；该取代吡咯烷化合物亚类的化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病；该取代吡咯烷化合物亚类的新化合物；包括所述取代吡咯烷化合物的药物制剂和/或包括给予所述取代吡咯烷化合物的治疗方法，特别是制备该新取代吡咯烷化合物的方法，以及其合成的新中间体、起始材料和/或部分步骤。
• HIV PROTEASE INHIBITORS
  申请人：Coburn Craig A.

  公开号：US20120142752A1

  公开（公告）日：2012-06-07

  Compounds of Formula (I) are disclosed; wherein X A , k, A, B, R 3A , R 3B , R 4 and R 5 are defined herein. The compounds of Formula (I) are HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  公开了化学式（I）的化合物；其中XA，k，A，B，R3A，R3B，R4和R5在此定义。化合物（I）是HIV蛋白酶抑制剂。化合物及其药学上可接受的盐可用于预防或治疗HIV感染以及预防，治疗或延迟艾滋病的发作。这些化合物及其盐可作为制药组合物的成分，可选地与其他抗病毒药物，免疫调节剂，抗生素或疫苗组合使用。
• Pentacyclic heterocycles
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US11358972B2

  公开（公告）日：2022-06-14

  The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

  本发明提供了式 (I) 至 (XVII) 所代表的化合物或其药学上可接受的盐类：